Valuation: Vcanbio Cell & Gene Engineering Corp., Ltd

Capitalization 11.49B 1.65B 1.41B 1.32B 1.22B 2.29B 149B 2.46B 15.13B 5.95B 71.15B 6.18B 6.05B 261B P/E ratio 2023
88.1x
P/E ratio 2024 87.7x
Enterprise value 10.09B 1.45B 1.24B 1.16B 1.08B 2.01B 131B 2.16B 13.29B 5.23B 62.47B 5.43B 5.31B 229B EV / Sales 2023
5.05x
EV / Sales 2024 4.67x
Free-Float
72.94%
Yield 2023 *
-
Yield 2024 -
More valuation ratios * Estimated data
Dynamic Chart
29/10/25 Vcanbio Cell & Gene Engineering Corp., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2025 CI
12/09/25 GASTECH-Swiss trader MET Group seeks US LNG to grow portfolio, Southeast Asia sales RE
10/09/25 Vcanbio Cell & Gene Engineering Gets Clinical Trial Approval for Pneumonia Treatment MT
27/08/25 Vcanbio Cell & Gene Engineering Corp., Ltd Reports Earnings Results for the Half Year Ended June 30, 2025 CI
05/08/25 Vcanbio Cell & Gene Engineering's Unit Gets Nod to Trial VUM02 Injection; Shares Up 3% MT
28/07/25 Vcanbio Cell & Gene Engineering Corp., Ltd agreed to acquire an additional 25% stake in Shanghai Vcanbio Jisheng Cell Technology Co., Ltd. from Shanghai Yanli Biotechnology Co., Ltd. for CNY 3.8 million. CI
07/07/25 Switzerland's Met Group buys Germany's KGE, boosting gas storage portfolio RE
24/06/25 China Grants Clinical Trial Approval for Vcanbio's Pneumonia Injection from Human Umbilical Cord Cells MT
24/04/25 Vcanbio Cell & Gene Engineering Corp., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2025 CI
18/12/24 Vcanbio Cell & Gene Engineering's Unit Gets Nod to Trial Ulcerative Colitis Drug MT
29/10/24 Vcanbio Cell & Gene Engineering Corp., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2024 CI
27/09/24 Vcanbio Unit Gets Clinical Trial Approval for Stem Cell Preparation for Large Intestine Inflammation MT
09/09/24 Vcanbio Cell & Gene Engineering Unit Gets China Clinical Trial Approval for Stem Cell Injection MT
More news
1 day-1.01%
1 week+3.58%
Current month+9.21%
1 month+4.08%
3 months+11.69%
6 months+3.93%
Current year+9.21%
More quotes
1 week 26.61
Extreme 26.61
28.56
1 month 24.92
Extreme 24.92
28.56
Current year 24.92
Extreme 24.92
28.56
1 year 18.88
Extreme 18.88
30.32
3 years 12.88
Extreme 12.88
30.32
5 years 12.88
Extreme 12.88
30.32
10 years 12.88
Extreme 12.88
44.68
More quotes
Manager TitleAgeSince
Chief Executive Officer 59 18/05/2020
Director of Finance/CFO 44 24/05/2022
Corporate Officer/Principal 55 31/01/2016
Director TitleAgeSince
Director/Board Member 59 06/02/2014
Chairman 55 15/05/2023
Chairman 61 25/03/2022
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
-1.01%+3.58%+47.96%+56.54% 1.82B
+0.09%-5.84%-1.73%+6.14% 14.84B
+1.60%-3.32%+185.04%+256.88% 13.77B
+0.08%-6.91% - - 7.45B
-1.29%-0.92%-3.55%+2.40% 6.73B
0.00%+4.60%-25.54%-40.61% 4.7B
-0.36%-5.86%-30.69%+23.59% 4.37B
-0.37%+2.50%-6.84%-45.65% 3.07B
+1.95%+8.34%+33.16%-51.60% 2.6B
+0.23%+4.32%+9.07%-15.73% 2.56B
Average -0.07%-0.43%+22.99%+21.33% 6.19B
Weighted average by Cap. -0.09%-2.22%+44.45%+61.44%
See all sector performances

Financials

2023 2024
Net sales 1.59B 228M 196M 182M 170M 316M 20.58B 341M 2.09B 824M 9.85B 855M 837M 36.08B 1.59B 227M 195M 182M 169M 315M 20.53B 340M 2.09B 822M 9.82B 853M 835M 35.98B
Net income 106M 15.27M 13.1M 12.2M 11.35M 21.18M 1.38B 22.83M 140M 55.17M 659M 57.26M 56.08M 2.42B 100M 14.39M 12.35M 11.5M 10.7M 19.97M 1.3B 21.53M 132M 52.01M 621M 53.97M 52.86M 2.28B
Net Debt -1.45B -208M -179M -167M -155M -289M -18.82B -312M -1.92B -753M -9B -782M -766M -32.99B -1.4B -201M -172M -161M -149M -279M -18.14B -301M -1.85B -726M -8.68B -754M -738M -31.8B
More financial data * Estimated data
Logo Vcanbio Cell & Gene Engineering Corp., Ltd
Vcanbio Cell & Gene Engineering Corp Ltd is a China-based company mainly engaged in the business of precision prevention, precision diagnosis and cell therapy. The Company operates two segments, including the service segment and the manufacturing segment. The Company’s products and services include cell testing preparation and storage services, research & development (R&D), production and sales of in vitro diagnostic raw materials, in vitro diagnostic reagents and medical devices, R&D, production and sales of biological genes, proteins, antibodies, pharmaceutical intermediates, and comprehensive agents for experiments, as well as genetic testing services. The Company mainly conducts businesses within the domestic market.
Employees
2,014
More about the company
Date Price Change Volume
14/01/26 27.52 ¥ -1.01% 22,542,170
13/01/26 27.80 ¥ +0.72% 22,242,430
12/01/26 27.60 ¥ +1.73% 15,852,420
09/01/26 27.13 ¥ +1.27% 9,840,354
08/01/26 26.79 ¥ +0.19% 8,536,700

End-of-day quote Shanghai S.E., January 13, 2026

More quotes

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 600645 Stock